Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05829226 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)
A Phase 1 study of MDS and AML, Adult Recurrent, sponsored by PureTech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 9
- Study locations
NCT05829226: Recruiting Phase 1 study of MDS and AML, Adult Recurrent, sponsored by PureTech.
NCT05829226 is a Phase 1 study of MDS and AML, Adult Recurrent that is actively recruiting participants, run by PureTech. The registered enrollment target is 90 participants, roughly in line with the 93-participant average among 22 other MDS trials with a reported enrollment target. The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05829226, a Phase 1 study of MDS and AML, Adult Recurrent, is actively recruiting participants, sponsored by PureTech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 9
- Study locations
Study Summary
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
Primary Outcome
Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG Decitabine
- DRUG LYT-200
Study Locations (9)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California Irvine Medical Center - Orange
Florida
- Baptist Health South Florida-Miami Cancer Institute - Miami
Kentucky
- Norton Healthcare-Norton Cancer Institute - Louisville
Massachusetts
- Mass. General Hospital-Harvard - Boston
Michigan
- Karmanos Cancer Institute - Detroit
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Rhode Island
- Rhode Island Hospital - Providence
Virginia
- Virginia Commonwealth University Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
What NCT05829226 shows while recruiting
NCT05829226 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, roughly in line with the 93-participant average among 22 other MDS trials with a reported enrollment target.
The record links to 2 conditions, with MDS appearing as the primary indexed condition, and to 4 interventions - of which Venetoclax is the first listed.
NCT05829226 lists 9 locations in 8 states (California, Florida, Kentucky).
Frequently Asked Questions
What is clinical trial NCT05829226 about?
NCT05829226 is a clinical study titled "A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)". A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/refractory, High-risk Myelodysplastic Syndrome (MDS)
What is the current status of trial NCT05829226?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2022-12-12. Estimated completion is 2026-03.
What conditions does trial NCT05829226 study?
This clinical trial studies the following conditions: MDS, AML, Adult Recurrent.
What interventions are being tested in trial NCT05829226?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), Decitabine (DRUG), LYT-200 (DRUG).
Who is sponsoring clinical trial NCT05829226?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05829226 being conducted?
This trial has 9 study locations across California, Florida, Kentucky, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for MDS
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05829226's enrollment target sits among peer trials
90 5th of 22 higher than 18 of 22 other MDS trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other MDS trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
RECRUITING · Phase 1
-
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
RECRUITING · Phase 1
-
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI